10-QPeriod: Q3 FY2011

CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2011

Filed November 3, 2011For Securities:CVS

Summary

CVS Health Corporation (CVS) reported solid revenue growth in the third quarter and first nine months of 2011, driven by its Pharmacy Services and Retail Pharmacy segments. Net revenues increased by 12.5% and 10.7% for the respective periods, largely attributable to a new long-term contract in Pharmacy Services and consistent same-store sales in Retail Pharmacy, bolstered by the acquisition of the UAM Medicare Part D Business. Despite revenue growth, gross profit margins saw some pressure, particularly in the Pharmacy Services segment, due to pricing compression and increased sharing of rebates. The company also highlighted its continued focus on operational efficiency and strategic growth initiatives, including significant share repurchases and capital expenditures for store development. Financially, CVS maintained a strong liquidity position with substantial cash flow from operations. The company completed a significant debt issuance and continued to execute its share repurchase programs, signaling confidence in its financial health and commitment to returning value to shareholders. While facing ongoing industry challenges like reimbursement pressures and generic drug introductions, CVS demonstrated resilience by growing its store base and improving operational leverage. The company continues to navigate a complex regulatory and competitive landscape, with ongoing litigation and investigations noted but not deemed material to its financial condition.

Financial Statements
Beta
Revenue$26.67B
Cost of Revenue$21.50B
Gross Profit$5.18B
Operating Expenses$3.59B
Operating Income$1.58B
Interest Expense$156.00M
Net Income$867.00M
EPS (Basic)$0.65
EPS (Diluted)$0.65
Shares Outstanding (Basic)1.33B
Shares Outstanding (Diluted)1.34B

Key Highlights

  • 1Net revenues increased by 12.5% for the three months ended September 30, 2011, and 10.7% for the nine months ended September 30, 2011, compared to the prior year periods.
  • 2The Pharmacy Services segment benefited from a new long-term contract and the acquisition of the UAM Medicare Part D Business, while the Retail Pharmacy segment saw growth driven by same-store sales and new store openings.
  • 3Gross profit margin in the Pharmacy Services segment experienced pressure due to pricing compression and changes in rebate sharing, impacting overall profitability metrics for that segment.
  • 4CVS Health continued its robust share repurchase program, authorizing a new $4.0 billion program and executing an accelerated share repurchase agreement.
  • 5Net cash provided by operating activities was strong at $5.0 billion for the nine months ended September 30, 2011, indicating healthy cash generation.
  • 6The company issued new senior notes totaling $1.5 billion to repay existing debt and for general corporate purposes.
  • 7Despite industry pressures like reimbursement rates and generic drug introductions, the company maintained its focus on expanding its retail footprint and improving operational efficiencies.

Frequently Asked Questions

CVS Health reported a significant increase in net revenues, up 12.5% to $26.7 billion for the three months ended September 30, 2011, compared to $23.7 billion in the same period of 2010. This growth was driven by both its Pharmacy Services and Retail Pharmacy segments.

The revenue growth in the Pharmacy Services segment was primarily fueled by a new long-term contract with a large health insurance carrier that became effective in January 2011, and the acquisition of the UAM Medicare Part D Business in April 2011. Additionally, increased claims processed and higher average revenue per mail choice claim contributed to the segment's performance.

The gross profit margin in the Pharmacy Services segment experienced pressure, decreasing from 7.4% to 6.2% for the three-month period and from 7.0% to 5.3% for the nine-month period. This was attributed to pricing compression from contract renewals, increased competition leading to more sharing of rebates and discounts from manufacturers, and the profitability profile of new contracts.

CVS Health demonstrated a strong commitment to shareholder returns through active share repurchase programs. The company authorized a new $4.0 billion repurchase program and executed a $1.0 billion accelerated share repurchase. Additionally, the company issued $1.5 billion in senior notes, strengthening its capital structure and providing funds for debt repayment and general corporate purposes.